ReviewHerz2012
Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.
Review in Herz, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis.Oxidative medicine and cellular longevity · 2020Pooled it
- Corticosteroids and Intravenous Immunoglobulin in Pediatric Myocarditis: A Meta-Analysis.Frontiers in pediatrics · 2019Pooled it
- Guideline
- Predictors of Extracorporeal Membrane Oxygenation Support for Children with Acute Myocarditis.BioMed research international · 2017Trial
- Pericardioscopy and epi- and pericardial biopsy - a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy.Heart failure reviews · 2013Trial
- Article
- Eosinophilic myocarditis in dilated cardiomyopathy: a case report.BMC cardiovascular disorders · 2025Article
- The Molecular Role of Immune Cells in Dilated Cardiomyopathy.Medicina (Kaunas, Lithuania) · 2023Review
- Fulminant Eosinophilic Myocarditis Without Peripheral Eosinophilia.Texas Heart Institute journal · 2023Article
- Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis.JACC. Basic to translational science · 2021Article
- Review
- Idiopathic eosinophilic myocarditis presenting with features of an acute coronary syndrome.Echo research and practice · 2020Article
- Severe eosinophilic myocarditis associated with modafinil in a patient with normal peripheral eosinophil count.Clinical research in cardiology : official journal of the German Cardiac Society · 2019Article
- Successful Treatment of Acute Fulminant Eosinophilic Myocarditis in a Patient with Ulcerative Colitis Using Steroid Therapy and Percutaneous Cardiopulmonary Support.Internal medicine (Tokyo, Japan) · 2019Article
- ADAR1p150 Forms a Complex with Dicer to Promote miRNA-222 Activity and Regulate PTEN Expression in CVB3-Induced Viral Myocarditis.International journal of molecular sciences · 2019Article
- The Diagnostic and Clinical Approach to Pediatric Myocarditis: A Review of the Current Literature.Open access Macedonian journal of medical sciences · 2019Review
- Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options.Frontiers in cardiovascular medicine · 2019Review
- Article
- Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy.Archives of medical science : AMS · 2018Article
- Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.Herz · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In inflammatory dilated cardiomyopathy and myocarditis there is--apart from heart failure and antiarrhythmic therapies--no alternative to an aetiologically driven specific treatment. Prerequisite are noninvasive and invasive biomarkers including endomyocardial biopsy and PCR on cardiotropic agents. This review deals with the different etiologies of myocarditis and inflammatory cardiomyopathy including the genetic background, the predisposition for heart failure and inflammation. It analyses the epidemiologic shift in pathogenetic agents in the last 20 years, the role of innate and aquired immunity including the T- and B-cell driven immune responses. The phases and clinical faces of myocarditis are summarized. Up-to-date information on current treatment options starting with heart failure and antiarrhythmic therapy are provided. Although inflammation can resolve spontaneously, specific treatment directed to the causative aetiology is often required. For fulminant, acute and chronic autoreactive myocarditis immunosuppressive treatment is beneficial, while for viral cardiomyopathy and myocarditis ivIg can resolve inflammation and is as successful as interferon therapy in enteroviral and adenoviral myocarditis. For Parvo B19 and HHV6 myocarditis eradication of the virus is still a problem by any of these treatment options. Finally, the potential of stem cell therapy has to be tested in future trials. In virus-negative, autoreactive perimyocardial disease a locoregional approach with intrapericardial instillation of high local doses of triamcinolone acetate has been shown to be highly efficient and with few systemic side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.